| 50.9619 0.362 (0.72%) | 04-19 14:33 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 63.76  |
1-year : | 66.76 |
| Resists | First : | 54.58 |
Second : | 57.15 |
| Pivot price | 53.69 |
|||
| Supports | First : | 50.43 |
Second : | 41.95 |
| MAs | MA(5) : | 51.47 |
MA(20) : | 54.28 |
| MA(100) : | 56.72  |
MA(250) : | 53.67 |
|
| MACD | MACD : | -1.6 |
Signal : | -1.3 |
| %K %D | K(14,3) : | 0 | D(3) : | 0 |
| RSI | RSI(14): 23.6 |
|||
| 52-week | High : | 63.25 | Low : | 45 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ BBP ] has closed above bottom band by 3.1%. Bollinger Bands are 44.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 50.76 - 51.25 | 51.25 - 51.54 |
| Low: | 49.36 - 50.02 | 50.02 - 50.42 |
| Close: | 49.69 - 50.74 | 50.74 - 51.38 |
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with at least one drug therapy approved by the U.S. Food and Drug Administration ("FDA") for marketing.
Wed, 17 Apr 2024
The 5 Best Biotech ETFs of 2024 - etf.com
Tue, 09 Apr 2024
5 Best Biotech ETFs To Buy - Insider Monkey
Tue, 09 Jan 2024
Biotech ETFs Stage Solid Comeback at the Start of 2024 - Yahoo Finance
Tue, 20 Sep 2022
Innovation Reigns In 10 Best-Performing ETFs Of The Last 3 Months - FA Mag
Thu, 04 Aug 2022
Biotech ETFs Advance on Speculation of a Takeover Bid for Global Blood Therapeutics - ETF Trends
Tue, 05 Jul 2022
Biotech ETFs Are Making a Comeback - ETF Trends
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|